Puma Biotechnology Insider Michael Patrick Miller Sells $121K of Stock
Michael Patrick Miller sold 15,000 shares of Puma Biotechnology, Inc. at $8.10 a share, worth $121K in total on Nov 11, 2026. Shares held after the trade: 66,000 (-18.5%).
Puma Biotechnology reported total revenue of $55.1 million for the third quarter of 2026, driven primarily by NERLYNX product sales. While the company remained profitable with a net income of $6.0 million, this was a decrease from $8.8 million in the prior year's third quarter due to higher research and development expenses.
Puma Biotechnology reported Q3 2026 financial results with total product revenue of $54.1 million, driven by sales of NERLYNX. The company reported GAAP net income of $6.0 million and raised its full-year 2026 net income guidance while continuing to advance its alisertib clinical development programs.
Term
Q3 2026
“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter.”
Alan H. Auerbach, Chairman, Chief Executive Officer and President
“We continue to anticipate increased year-over-year demand for NERLYNX, while we continue to advance alisertib across our ALISCA® clinical development programs.”
Alan H. Auerbach, Chairman, Chief Executive Officer and President